Suominen reports Q2 results on Aug 7. We believe H1’25 earnings will remain rather flat, but H2 shou...
Redeye gives an initial comment on the Leqembi royalty for Q2 and the presentations from AAIC.
Cancom Q2 PW and cut FY'25 EBITA guidance by -25%, stock -8% Blames reluctant customers, and particu...
Redeye comments on GiG’s preliminary Q2-results which were in line with our forecasts and the announ...
Adtraction redovisade minskad nettoomsättning och EBITA i det andra kvartalet.
Redeye views the recently announced progress on US reimbursements positively, as a second payor has ...
Mendus has fortified its intellectual property (IP) profile for lead candidate, vididencel, with the...
NoHo Partners will publish its Q2 2025 results on 5 August, at around 8:00 EET.
Redeye provides a comment on DalaVind’s divestment of Fageråsen, an onshore wind project of more tha...
Vaisala’s Q2 fell short of our estimates due to weaker than expected performance in W&E.
Physitrack delivered a solid Q2, highlighted by margin expansion, positive free cash flow, and great...
Redeye states that Gapwaves delivered a solid report with beats across key metrics.
Soft Q2, but heading in the right direction We forecast Q2 sales of EUR 27.
W&E headwinds had a greater impact than we anticipated in Q2, resulting in net sales coming in sligh...
Redeye updates its estimates and valuation following Eniro's Q2 2025 report and a change of lead ana...
